Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1562-1569

  Vasey, P A ^a   Shulman, L N ^a   Campos, S ^a   Davis, J ^a   Gore, M ^a   Johnston, S ^a   Kirn, D H ^a   O'Neill, V ^a   Siddiqui, N ^a   Seiden, M V ^a   Kaye, S B ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONYX 015;

ABDOMINAL PAIN; ADENOVIRUS; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EPITHELIUM TUMOR; FEMALE; FLU LIKE SYNDROME; GENE DELETION; GENE MUTATION; HUMAN; MALAISE; MYALGIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PLAQUE FORMING CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ADULT; AGED; ANTIBODIES, VIRAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

EID: 0037087621     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1562     Document Type: Article

References (35)

1. Estimates of cancer incidence and mortality in Europe in 1995
2. Update in the management of advanced ovarian carcinoma
3. Predictors of response to subsequent chemotherapy in platinum pre-treated ovarian cancer: A multivariate analysis of 704 patients
4. Wild type p53 mediates apoptosis by EIA, Which is inhibited by EIB
5. Enhanced expression of p 53 in human cells infected with mutant adenoviruses
6. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
7. Ovarian cancer, from the laboratory to thc clinic: Challenges for the future
8. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis
9. Domains required for in vitro association between the cellular p 53 and the adenovirus 2 E1B 55K proteins
10. A mutant adenovirus which selectively replicates in tumour cells with non-functional p53
11. Replication and cytolysis of an EIB-attenuated adenovirus in drug resistant ovarian tumour cells is associated with reduced apoptosis
12. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
13. p53-independent and -dependent requirements for EIB- 55kD in adenovirus type 5 replication
14. p53 status does not determine outcome of E1B 55kilodalton mutant adenovirus lytic infection
15. Efficacy of a replication-sensitive adenovirns against ovarian carcinomatosis is dependent on tumour burden, viral replication and p 53 status
16. The incidence of p 53 mutations increases with progression of head and neck cancer
17. A phase I study of ONYX-015, and EIB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
18. Rationale for and complications of intraperitoneal chemotherapy
19. ONYX-015, an E1B gene-attenuated adenovirus, causes tumour-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
20. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
21. Studies on the use of viruses in the treatment of carcinoma of the cervix
22. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumours after intraperitoneal chemotherapy: A comparison with systemic chemotherapy
23. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p 53 functional status or route of administration
24. The effect of volume on the distribution of substances instilled into the peritoneal cavity
25. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis
26. Immunology taught by viruses
27. Cellular immunity to viral antigens limits EIB-deleted adenoviruses for gene therapy
28. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
29. Physiologically based pharmacokinetic model for specific and non-specific monoclonal antibodies and fragments in normal tissues and human tumour xenografts in nude mice
30. Induction of susceptibility to tumour necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis
31. p53 status and the efficacy of cancer therapy in vivo
32. Carcinoma cells become sensitive to DNA-damaging agents by the expression of the adenovirus EIA gene
33. Structure and function of the p53 tumour suppressor gene: Clues for rational cancer therapeutic strategies
34. Cisplatin, camptothecin and Taxol sensitivities of cells with p53-associated multidrug resistance
35. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma